Thanks, very impressive stuff. Looking over the July presentation I like this slide showing CDH17 space. Do you know of any progress or expected updates on the CAR-NK CDH17 program by Chimeric?
Also I was looking on Arbele Bio site, and they state they own the patent to target CDH17 gastrointestinal cancers - do you know if this impacts Chimeric's addressable market??
https://www.arbelebio.com/cadherin-17
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.747M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.858K | 619.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 66 | 58647032 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 107164382 | 32 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| CHM (ASX) Chart |